Natalizumab adverse events are rare in patients with multiple sclerosis

被引：13

作者：

Fragoso, Yara Dadalti ^{[1
]}

Alves-Leon, Soniza Vieira ^{[2
]}

Arruda, Walter Oleschko ^{[3
]}

Carvalho, Margarete de Jesus ^{[4
]}

Comini-Frota, Elizabeth Regina ^{[5
]}

Correa, Eber Castro ^{[6
]}

Brito Ferreira, Maria Lucia ^{[7
]}

da Gama, Paulo Diniz ^{[8
]}

Gomes, Sidney ^{[9
,10
]}

Magno Goncalves, Marcus Vinicius ^{[11
]}

Kaimen-Maciel, Damacio Ramon ^{[12
]}

Mendes, Maria Fernando ^{[13
]}

Morales, Rogerio Rizo ^{[14
]}

Muniz, Andre ^{[15
]}

Salgado, Pedro Rippel ^{[16
]}

Ruocco, Heloisa Helena ^{[17
]}

Bezerra de Albuquerque, Livia Brito ^{[7
]}

Bidin Brooks, Joseph Bruno ^{[1
]}

Fezer, Leticia ^{[2
]}

Georgetto, Sergio ^{[12
]}

Lopes, Josiane ^{[12
]}

Malfetano, Fabiola Rachid ^{[2
]}

Meira, Isabella D'Andrea ^{[2
]}

Silva Oliveira, Celso Luis ^{[1
]}

Meneses de Oliveira, Francisco Tomaz ^{[9
,10
]}

Safanelli, Fabiana ^{[11
]}

Satomi, Massaco ^{[16
]}

机构：

[1] Univ Metropolitana Santos UNIMES, Santos, SP, Brazil

[2] Univ Fed Rio de Janeiro UFRJ, Rio De Janeiro, RJ, Brazil

[3] Univ Fed Parana UFPR, Curitiba, PR, Brazil

[4] Fac Med ABC FMABC, Santo Andre, SP, Brazil

[5] Univ Fed Minas Gerais UFMG, Belo Horizonte, MG, Brazil

[6] CLINEN, Brasilia, DF, Brazil

[7] Hosp Restauracao, Recife, PE, Brazil

[8] Pontificia Univ Catolica Sao Paulo PUC SP, Sorocaba, SP, Brazil

[9] Hosp Beneficencia Portuguesa Sao Paulo, Sao Paulo, Brazil

[10] Hosp Paulistano, Sao Paulo, Brazil

[11] Univ Regiao Joinville UNIVILLE, Joinville, SC, Brazil

[12] Univ Estadual Londrina UEL, Londrina, PR, Brazil

[13] Fac Ciencias Med Santa Casa Sao Paulo FCMSCSP, Sao Paulo, Brazil

[14] Univ Fed Uberlandia UFU, Uberlandia, MG, Brazil

[15] Hosp Sao Rafael Salvador, Salvador, BA, Brazil

[16] Univ Fed Mato Grosso Sul UFMS, Campo Grande, MS, Brazil

[17] Ctr Atendimento Esclerose Multipla, Jundiai, SP, Brazil

来源：

ARQUIVOS DE NEURO-PSIQUIATRIA | 2013年 / 71卷 / 03期

关键词：

multiple sclerosis; natalizumab; adverse events; antibodies; monoclonal; INFUSION REACTIONS;

D O I：

10.1590/S0004-282X2013000300002

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Objective: To assess the prevalence and the profile of adverse events (AE) of natalizumab in patients with multiple sclerosis (MS). Methods: Data collection from neurologists attending to patients with MS at specialized units in Brazil. Results: Data from 103 patients attending the infusion centers of 16 MS units in 9 Brazilian states were included in the study. The total number of infusions was 1,042. Seventy-nine patients (76.7%) did not present any AE. Twenty-four patients (23.3%) presented only mild AE. There were three major AE, including two deaths. These three occurrences, although not necessarily being drug-related, must be taken into consideration. Conclusion: The profile of AEs for natalizumab shows that 97% of patients have none or only mild AE. However, still due to safety worries, the use of this medication should be restricted to MS units under the care of specialized neurologists.

引用

页码：137 / 141

页数：5

共 50 条

[21] Natalizumab in the treatment of patients with multiple sclerosis -: First experience
Mareckova, Helena
Havrdova, Eva
Krasulova, Eva
Vankova, Zdenka
Koberova, Michaela
Sterzl, Ivan
AUTOIMMUNITY, PT B: NOVEL APPLICATIONS OF BASIC RESEARCH, 2007, 1110 : 465 - 473
[22] Immune surveillance in multiple sclerosis patients treated with natalizumab
Stüve, O
Marra, CM
Jerome, KR
Cook, L
Cravens, PD
Cepok, S
Frohman, EM
Phillips, JT
Arendt, G
Hemmer, B
Monson, NL
Racke, MK
ANNALS OF NEUROLOGY, 2006, 59 (05) : 743 - 747
[23] JCV detection in multiple sclerosis patients treated with natalizumab
Sadiq, Saud A.
Puccio, Lauren M.
Brydon, Edward W. A.
JOURNAL OF NEUROLOGY, 2010, 257 (06) : 954 - 958
[24] Effect of natalizumab on B lymphocytes in patients with multiple sclerosis
Putzki, N.
Kumar, M.
Grosse-Wilde, H.
Kreuzfelder, E.
MULTIPLE SCLEROSIS, 2007, 13 : S158 - S158
[25] Natalizumab was well-tolerated in patients with multiple sclerosis
Reactions Weekly, 1999, 750 (1) : 4 - 4
[26] JC virus in multiple sclerosis patients treated with natalizumab
Inmaculacla Dominguez-Mozo, Maria
Alvarez-Lafuente, Roberto
Garcia-Montojo, Marta
De las Heras, Virginia
Manuel Bartolome, Francisco
Arroyo, Rafael
MULTIPLE SCLEROSIS, 2008, 14 : S39 - S39
[27] Alemtuzumab for patients with relapsing multiple sclerosis after Natalizumab
Pena Martinez, J.
Lopez Real, A. M.
Oterino Duran, A.
Costa Arpin, E.
Gonzalez Suarez, I.
Fernandez Fernandez, E.
Rodriguez Regal, A.
Solar Sanchez, D. M.
Garcia Estevez, D. A.
Rodriguez Rodriguez, M.
Lorenzo Gonzalez, J. R.
Prieto Gonzalez, J. M.
Fernandez Uria, D.
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 306 - 306
[28] Binucleated lymphocytes in patients with multiple sclerosis treated with natalizumab
Leclerc, Mathieu
Lesesve, Jean-Francois
Gaillard, Baptiste
Troussard, Xavier
Tourbah, Ayman
Debouverie, Marc
Daliphard, Sylvie
Delmer, Alain
LEUKEMIA & LYMPHOMA, 2011, 52 (05) : 910 - 912
[29] Natalizumab: Risk Stratification of Individual Patients with Multiple Sclerosis
Carmen Tur
Xavier Montalban
CNS Drugs, 2014, 28 : 641 - 648
[30] Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment
Tur, Carmen
Tintore, Mar
Vidal-Jordana, Angela
Bichuetti, Denis
Nieto Gonzalez, Pablo
Jesus Arevalo, Maria
Arrambide, Georgina
Anglada, Elisenda
Galan, Ingrid
Castillo, Joaquin
Jordi Rio, Carlos Nos
Isabel Martin, Maria
Comabella, Manuel
Sastre-Garriga, Jaume
Montalban, Xavier
PLOS ONE, 2013, 8 (12):

← 1 2 3 4 5 →